StopUMTS Logo
how to get rid of moles 
Zoeken
   
Voorlichting
21/09/17EHS en toch een smartphon
01/09/17WiFi vrije scholen (kaart
Artikelen
25/09/175G: Geschenk of infras
20/09/17IoT 5
20/09/17Harmonische vervorming
20/09/17Vitamin B17: The Greatest
19/09/17Burn-out (toename)
19/09/17Schildklierkanker, toenam
Berichten Nederland
28/09/17Nieuw boek: DE DRAADLOZE
21/09/17GGD Utrecht: een nieuw ge
20/09/17Ruimte in de ether voor 5
20/09/17De Impact-Academy en onze
18/09/17Vereniging tegen de Kwakz
Berichten België
01/07/17Verdubbeling burn-out in
26/06/17Voorstel van resolutie vo
Berichten Internationaal
21/09/17USA: Monterey County Proc
20/09/17USA: nieuwe 5G ellende: D
19/09/17USA: De jongeren van nu g
19/09/17USA: 5G opponents launch
Ervaringen | Appellen/oproepen
24/09/17Lichaamspanning en ele
18/09/17WiFi 2,4 GHz en 5 GHz; ee
18/09/17''Why I Don't Have a Mobi
Onderzoeken
20/09/17National Toxicology Progr
08/09/17Anxiety-like behavioural
07/09/17The mere presence of your
Veel gestelde vragen
13/05/17Vakantie? Witte zo
10/07/16Zeven veel gestelde vrage
Juridische informatie
19/09/17USA situatie: WOZ waarded
10/09/17Rechter: Staat moet lucht
31/08/17InPower Movement: Early r
Oproepen
29/11/17Raadsmarkt ZENDMASTEN &
11/11/17Cursus ‘Straling meten
29/09/17EHS regionale contactdage
Folders
10/06/17Brochures, folders, websi
29/04/16USA: Meer dan 50 tips voo
Briefwisselingen | Archief: 2008, 2005
10/07/17Brief naar de gemeente C.
14/06/17Mail naar 'De Monitor' na
Illustraties
 Algemeen
 Fotoalbum zendmasten
 Wetenschappelijke illustraties
USA/Brazilië: Behandeling leverkanker met zeer zwakke elektromagnetische velden.    
Ga naar overzicht berichten in: Onderzoeken

USA/Brazilië: Behandeling leverkanker met zeer zwakke elektromagnetische velden.
dinsdag, 16 augustus 2011 - Dossier: Algemeen


Gerelateerd artikel: Berichten%20Internationaal/5991

Bron: British Journal of Cancer 9 August 2011; doi: 10.1038/bjc.2011.292

Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields

F P Costa 1, A C de Oliveira 1, R Meirelles 1, M C C Machado 1, T Zanesco 1, R Surjan 1,
M C Chammas 2, M de Souza Rocha 2,
D Morgan 3,
A Cantor 4,
J Zimmerman 5,
I Brezovich 6,
N Kuster 7,
A Barbault 8 and
B Pasche 5

1.
Department of Transplantation and Liver Surgery, Hospital das Clínicas da Faculdade de Medicina, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, São Paulo 05403-000, Brazil

2.
Department of Radiology, Hospital das Clínicas, University of São Paulo, São Paulo 05403-000, Brazil

3.
Department of Radiology, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

4.
Biostatistics and Bioinformatics Shared Facility, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

5.
Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, 1802 6th Ave South, NP 2566, Birmingham, AL 35294-3300, USA

6.
Department of Radiation Oncology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA

7.
IT'IS Foundation, Swiss Federal Institute of Technology, Zurich, Switzerland

8.
Rue de Verdun 20, Colmar 68000, France

Correspondence:
Dr FP Costa, E-mail: fredericoperegocosta@gmail.com;
Dr B Pasche, E-mail: Boris.Pasche@ccc.uab.edu

Abstract
Background:

Therapeutic options for patients with advanced hepatocellular carcinoma (HCC) are limited. There is emerging evidence that the growth of cancer cells may be altered by very low levels of electromagnetic fields modulated at specific frequencies.

Methods:

A single-group, open-label, phase I/II study was performed to assess the safety and effectiveness of the intrabuccal administration of very low levels of electromagnetic fields amplitude modulated at HCC-specific frequencies in 41 patients with advanced HCC and limited therapeutic options. Three-daily 60-min outpatient treatments were administered until disease progression or death. Imaging studies were performed every 8 weeks. The primary efficacy end point was progression-free survival greater than or equal to6 months. Secondary efficacy end points were progression-free survival and overall survival.

Results:
Treatment was well tolerated and there were no NCI grade 2, 3 or 4 toxicities. In all, 14 patients (34.1%) had stable disease for more than 6 months. Median progression-free survival was 4.4 months (95% CI 2.1–5.3) and median overall survival was 6.7 months (95% CI 3.0–10.2). There were three partial and one near complete responses.

Conclusion:
Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of antitumour effects in patients with advanced HCC.


Voor het originele abstract zie:
www.nature.com/bjc/journal/vaop/ncurrent/abs/bjc2011292a.html .


Ga terug naar het hoofdmenu
Afdrukken | Vragen | RSS | Disclaimer